Invasive candidiasis: update on current pharmacotherapy options and future perspectives.

Abstract

INTRODUCTION:

Invasive candidiasis (IC), mainly candidemia, is a leading cause of morbidity and mortality among immunocompromised patients and those admitted to intensive care units. Despite the recognition of risk factors and advances in disease prevention, Candida-related hospitalizations and mortality continue to rise. For treatment, four classes of older and newer antifungal agents are currently available. Adjunctive immunotherapies and a monoclonal antibody against heat shock protein 90 (efungumab) are promising novel therapeutic approaches.

AREAS COVERED:

In this article, approaches and therapeutic agents for candidemia and other forms of IC are reviewed.

EXPERT OPINION:

The thorough understanding of the available antifungal agents in combination with the increasing knowledge of the mechanisms that underlie the pathogenesis of Candida infections and the development of newer approaches such as efungumab and immunotherapy with adjunctive cytokines may improve the prognosis of patients with life-threatening invasive Candida infections.

• Authors: Athanasios Tragiannidis, Christos Tsoulas, Kornelius Kerl, Andreas H Groll
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Vol. 14 Issue 11 Pg. 1515-28 (Aug 2013) ISSN: 1744-7666 [Electronic] England
• PMID: 23724798 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antifungal Agents
• efungumab

Topics

• Animals
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antifungal Agents (therapeutic use)
• Candidiasis, Invasive (therapy)
• Humans
• Immunotherapy